Every 10-Q that VIVOS INC (RDGL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RDGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RDGL filings page.
Vivos Inc. (RDGL) reported limited commercial activity and continuing losses for the six months ended June 30, 2026. Revenue was $72,468, primarily from IsoPet® product and related items, but cost of goods sold exceeded revenue, resulting in a gross loss. Operating expenses of $1.19 million produced an operating loss of $1.20 million, and after a $847,628 loss on share and warrant exchanges, the net loss reached $2,015,034.
Cash increased to $2,336,022, driven by $2,203,800 raised via Regulation A+ equity offerings and associated warrants, while total liabilities remained low at $123,955. The company has an accumulated deficit of $90.4 million and discloses that current cash is insufficient for its plans, estimating a need for about $3.0 million per year and $9.0 million over the next 36 months to fund operations and clinical development.
Management states there is substantial doubt about the ability to continue as a going concern absent additional capital. Strategically, Vivos highlights progress in its Precision Radionuclide Therapy™ platform, including FDA Breakthrough Device status, approval of an Early Feasibility IDE in July 2026 for a first-in-human study at Mayo Clinic, expansion of its IsoPet® animal-therapy network, and the consolidation of Vivos Scientific India LLP as a variable interest entity to support international clinical and manufacturing activities.
Vivos Inc. reported a larger quarterly loss while modestly growing early revenue as it develops its radionuclide cancer therapies. For the three months ended March 31, 2026, revenue was $36,068, up from $26,748, mainly from IsoPet® animal treatments and related products.
The company recorded a net loss of $1,184,845 versus $834,696 a year earlier, driven by operating expenses and a $651,628 loss on a warrant exchange. Cash was $2,525,782 with negative operating cash flow of $429,861. Management states there is substantial doubt about Vivos’ ability to continue as a going concern and estimates it needs about $3.0 million per year, or $9.0 million over 36 months, to fund planned activities.
To address this, Vivos continues to raise capital under its qualified Regulation A+ offerings, including new shares and warrants sold in March and April 2026. The company is advancing its IsoPet® veterinary business, pursuing FDA approval for RadioGel® human use, and building U.S. and Indian manufacturing and clinical infrastructure.
Vivos Inc (RDGL) reported Q3 2025 results. For the nine months ended September 30, 2025, revenue was $43,627 versus $23,000 a year ago, while Q3 revenue was $1,879 versus $5,000. The company posted a nine‑month operating loss of $2,069,328 and a net loss of $1,987,503.
Cash was $2,202,109 as of September 30, 2025. Operating cash use totaled $1,518,189 for the period, partially offset by $1,507,750 from financing activities, including $1,506,250 raised via a Regulation A+ equity issuance and related warrants. Shares outstanding were 454,664,957 as of November 11, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and estimates it requires approximately $3.0 million annually to maintain operations and about $9.0 million over 36 months for clinical and commercialization plans. The Board approved Vivos Scientific India LLP on September 17, 2025, established October 1, 2025, to support manufacturing and human therapy initiatives.